- The New York Times had another article Thursday on the investigation into the Chinese supply of heparin. Pharmalot had this related post Friday.
- FTC Commissioner Jon Leibowitz wrote an editorial for the Washington Post Monday on "reverse-payment" settlements (or "pay-for-delay" settlements), and the FTC’s recently filed case against Cephalon, in particular.
- Dow Jones reported Monday that Apotex and Pfizer settled their patent litigation over generic Neurontin (gabapentin). Pfizer’s cases against Eon Labs, Purepac and Teva are continuing.
- FDA Law Blog had an interesting post on a long-shot citizen petition filed by Apotex, who is seeking to recover its 180-day exclusivity on generic Plavix (clopidogrel).
- Also last week, FDA Law Blog posted a draft of Rep. Eshoo’s biosimilar’s bill. Word on the street is that it has little chance of passing.
- Pharmalot reported last week that growth in sales of generic drugs slowed to just 3.8% last year, largely due to increased competition.
Recent Posts
- Hikma v. Vanda: Oral Argument Recap
- Teva v. Lilly should not be read as creating a new 112 rule for method of use claims
- Should ANDA filers be using the PTAB to mount early challenges to OB patents?
- Switching to WordPress
- Judge Hughes concurrence highlights post grant review appeal standing issue for pharma cases
Orange Book Blog 
Leave a comment